<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychooncology</journal-id><journal-id journal-id-type="iso-abbrev">Psychooncology</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1611</journal-id><journal-id journal-id-type="publisher-id">PON</journal-id><journal-title-group><journal-title>Psycho-Oncology</journal-title></journal-title-group><issn pub-type="ppub">1057-9249</issn><issn pub-type="epub">1099-1611</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25753889</article-id><article-id pub-id-type="pmc">5006840</article-id><article-id pub-id-type="doi">10.1002/pon.3794</article-id><article-id pub-id-type="publisher-id">PON3794</article-id><article-categories><subj-group subj-group-type="overline"><subject>Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Papers</subject></subj-group></article-categories><title-group><article-title>A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN)<xref ref-type="fn" rid="pon3794-note-0030">&#x02020;</xref>
</article-title><alt-title alt-title-type="right-running-head">Brief cognitive behavioural intervention for men with hot flushes</alt-title><alt-title alt-title-type="left-running-head">E. Stefanopoulou <italic>et al.</italic></alt-title></title-group><contrib-group><contrib id="pon3794-cr-0001" contrib-type="author"><name><surname>Stefanopoulou</surname><given-names>Evgenia</given-names></name><xref ref-type="aff" rid="pon3794-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="pon3794-cr-0002" contrib-type="author"><name><surname>Yousaf</surname><given-names>Omar</given-names></name><xref ref-type="aff" rid="pon3794-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="pon3794-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="pon3794-cr-0003" contrib-type="author"><name><surname>Grunfeld</surname><given-names>Elizabeth A.</given-names></name><xref ref-type="aff" rid="pon3794-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="pon3794-cr-0004" contrib-type="author" corresp="yes"><name><surname>Hunter</surname><given-names>Myra S.</given-names></name><xref ref-type="aff" rid="pon3794-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="pon3794-aff-0001"><label><sup>1</sup></label><institution>Institute of Psychiatry, Psychology and Neuroscience, King's College London</institution><named-content content-type="city">London</named-content><country country="GB">UK</country></aff><aff id="pon3794-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Centre for Technology Enabled Health Research</named-content><institution>Coventry University</institution><named-content content-type="city">Coventry</named-content><country country="GB">UK</country></aff><aff id="pon3794-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Psychology</named-content><institution>University of Bath</institution><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence to: Institute of Psychiatry, Psychology and Neuroscience, King's College London, Department of Psychology, 5th Floor Bermondsey Wing, Guy's Campus, London Bridge, London SE1 9RT, England. E&#x02010;mail: <email>myra.hunter@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2015</year></pub-date><volume>24</volume><issue>9</issue><issue-id pub-id-type="doi">10.1002/pon.v24.9</issue-id><fpage>1159</fpage><lpage>1166</lpage><history><date date-type="received"><day>10</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>02</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>02</day><month>11</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 John Wiley & Sons, Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. <italic>Psycho&#x02010;Oncology</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:PON-24-1159.pdf"/><abstract id="pon3794-abs-0001"><title>Abstract</title><sec id="pon3794-sec-0001"><title>Objective</title><p>Hot flushes and night sweats (HFNS) are experienced by up to 80% of prostate cancer patients undergoing androgen deprivation therapy (ADT). This study evaluates the effects of a guided self&#x02010;help cognitive behavioural therapy (CBT) intervention on HFNS problem&#x02010;rating (primary outcome), HFNS frequency, mood and health&#x02010;related quality of life (secondary outcomes) in patients undergoing ADT.</p></sec><sec id="pon3794-sec-0002"><title>Methods</title><p>Patients reporting treatment&#x02010;induced HFNS were randomly assigned to CBT (<italic>n</italic>&#x02009;=&#x02009;33) or treatment as usual (TAU) (<italic>n</italic>&#x02009;=&#x02009;35), stratified for cancer type. The CBT intervention included a booklet, CD plus telephone contact during a 4&#x02010;week period. Validated self&#x02010;report questionnaires were completed at baseline, 6&#x000a0;weeks and 32&#x000a0;weeks after randomisation. The primary outcome was HFNS problem rating (perceived burden of HFNS) at 6&#x000a0;weeks after randomisation. Potential moderators and mediators were examined. Data analysis was conducted on a modified intention&#x02010;to&#x02010;treat basis.</p></sec><sec id="pon3794-sec-0003"><title>Results</title><p>Compared with TAU, CBT significantly reduced HFNS problem rating (adjusted mean difference: &#x02212;1.33, 95% CI &#x02212;2.07 to &#x02212;0.58; <italic>p</italic>&#x02009;=&#x02009;0.001) and HFNS frequency (&#x02212;12.12, 95% CI &#x02212;22.39 to &#x02212;1.84; <italic>p</italic>&#x02009;=&#x02009;0.02) at 6&#x000a0;weeks. Improvements were maintained at 32&#x000a0;weeks, but group differences did not reach significance. There were significant reductions in negative HFNS Beliefs and Behaviours following CBT, but not in mood or quality of life.</p></sec><sec id="pon3794-sec-0004"><title>Conclusions</title><p>Guided self&#x02010;help CBT appears to be a safe and effective brief treatment for men who have problematic HFNS following prostate cancer treatments. Further research might test the efficacy of the intervention in a multicentre trial. &#x000a9; 2015 The Authors. <italic>Psycho&#x02010;Oncology</italic> published by John Wiley &#x00026; Sons Ltd.</p></sec></abstract><counts><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>pon3794</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>pon3794-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:31.08.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="pon3794-cit-0000">
<string-name>
<surname>Stefanopoulou</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Yousaf</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Grunfeld</surname>, <given-names>E. A.</given-names>
</string-name>, and <string-name>
<surname>Hunter</surname>, <given-names>M. S.</given-names>
</string-name> (<year>2015</year>) <article-title>A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN)</article-title>. <source>Psycho&#x02010;Oncology</source>, <volume>24</volume>: <fpage>1159</fpage>&#x02013;<lpage>1166</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1002/pon.3794">10.1002/pon.3794</ext-link>.<pub-id pub-id-type="pmid">25753889</pub-id></mixed-citation>
</p></notes><notes><fn-group><fn id="pon3794-note-0030"><label>&#x02020;</label><p>The copyright line for this article was changed on 17 April 2015 after original online publication.</p></fn></fn-group></notes></front><body><sec id="pon3794-sec-0005"><title>Introduction</title><p>Prostate cancer is the most common cancer among men in the United Kingdom and the second leading cause of cancer related death in men in the Western world <xref rid="pon3794-bib-0001" ref-type="ref">1</xref>. Androgen deprivation therapy (ADT) is prescribed to inhibit cancer progression <xref rid="pon3794-bib-0002" ref-type="ref">2</xref> but is associated with debilitating side effects, including hot flushes and night sweats (HFNS), that affect up to 80% of men having ADT <xref rid="pon3794-bib-0003" ref-type="ref">3</xref>, <xref rid="pon3794-bib-0004" ref-type="ref">4</xref>. HFNS are not well understood; reductions in androgen levels are believed to alter the function of brain neurotransmitters, leading to disruption of the thermoregulatory system in the hypothalamus <xref rid="pon3794-bib-0004" ref-type="ref">4</xref>, <xref rid="pon3794-bib-0005" ref-type="ref">5</xref>. If left untreated, HFNS are associated with sleep disturbance, distress and reduced quality of life <xref rid="pon3794-bib-0006" ref-type="ref">6</xref>, <xref rid="pon3794-bib-0007" ref-type="ref">7</xref>, and reduced treatment adherence <xref rid="pon3794-bib-0004" ref-type="ref">4</xref>, <xref rid="pon3794-bib-0005" ref-type="ref">5</xref>. The symptoms tend to be frequent <xref rid="pon3794-bib-0008" ref-type="ref">8</xref>, <xref rid="pon3794-bib-0009" ref-type="ref">9</xref> and can persist for several years <xref rid="pon3794-bib-0010" ref-type="ref">10</xref>.</p><p>There are few safe and effective treatments for men with HFNS. A systematic review of treatments for HFNS in prostate cancer patients concluded that diethylstilbestrol, megestrol acetate and medroxyprogesterone are the most effective treatments, but all have side&#x02010;effects that are not well tolerated <xref rid="pon3794-bib-0004" ref-type="ref">4</xref>. With an increasing number of prostate cancer patients being diagnosed <xref rid="pon3794-bib-0011" ref-type="ref">11</xref>, there is a pressing need for safe, acceptable and effective treatments to help prostate cancer survivors manage HFNS.</p><p>There is evidence that cognitive behavioural therapy (CBT) is a safe and effective intervention for reducing the impact of HFNS and improving psychosocial functioning for menopausal women <xref rid="pon3794-bib-0012" ref-type="ref">12</xref> and breast cancer survivors <xref rid="pon3794-bib-0013" ref-type="ref">13</xref>, <xref rid="pon3794-bib-0014" ref-type="ref">14</xref>. This relatively brief intervention is effective when delivered in groups and in a guided self&#x02010;help format <xref rid="pon3794-bib-0012" ref-type="ref">12</xref>, <xref rid="pon3794-bib-0013" ref-type="ref">13</xref>, <xref rid="pon3794-bib-0014" ref-type="ref">14</xref>, <xref rid="pon3794-bib-0015" ref-type="ref">15</xref>, and is based on a cognitive model of HFNS <xref rid="pon3794-bib-0016" ref-type="ref">16</xref>. To our knowledge CBT has not yet been investigated in prostate cancer patients undergoing ADT who are experiencing troublesome HFNS.</p><p>MANCAN is a randomised controlled trial of guided self&#x02010;help CBT compared with treatment as usual (TAU). We hypothesised that guided self&#x02010;help CBT would be more effective than TAU in reducing HFNS problem&#x02010;rating (the extent to which HFNS are bothersome and interfere with life) <xref rid="pon3794-bib-0017" ref-type="ref">17</xref>, <xref rid="pon3794-bib-0018" ref-type="ref">18</xref>. Secondary outcomes include the effects on HFNS frequency, sternal skin conductance monitoring <xref rid="pon3794-bib-0019" ref-type="ref">19</xref>, mood and quality of life. The trial was funded by Prostate Cancer UK and registered with the UK Clinical Research Network (UKCRN; Trial ID: 10904). Ethical approval was obtained from South East London 2 Research Ethics Subcommittee, reference: 11/LO/1114. The authors have no conflicts of interests.</p></sec><sec id="pon3794-sec-0006"><title>Methods</title><sec id="pon3794-sec-0007"><title>Design and participants</title><p>Guided self&#x02010;help CBT and TAU control group were compared in a randomised controlled trial. The study design is described in the trial protocol <xref rid="pon3794-bib-0020" ref-type="ref">20</xref>. Prostate cancer patients were recruited by nurse specialists and medical staff from oncology and urology clinics in London, UK, between April 2012 and October 2013. Inclusion criteria were: English&#x02010;speaking men over 18&#x000a0;years old, undergoing ADT and having problematic HFNS [score&#x02009;&#x0003e;&#x02009;2 on the Hot Flush Rating Scale (HFRS) <xref rid="pon3794-bib-0021" ref-type="ref">21</xref> for at least 1&#x000a0;month and a minimum weekly frequency of 10]. Exclusion criteria were: undergoing current radiation therapy, chemotherapy and having medical/psychiatric conditions that would affect ability to participate.</p></sec><sec id="pon3794-sec-0008"><title>Procedures</title><p>Potentially eligible patients were screened by telephone (by ES); those meeting the criteria were sent study information and baseline questionnaires. Following consent and return of questionnaires, they attended a short clinical interview (with ES), and the Sternal Skin Conductance (SSC) monitor (see measures) was fitted for 48&#x000a0;h; at the end of the interview they were informed of their group allocation (CBT or TAU) (see Figure <xref rid="pon3794-fig-0001" ref-type="fig">1</xref>).</p><fig fig-type="Figure" xml:lang="en" id="pon3794-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>CONSORT diagram showing patient flow through the trial CBT&#x02009;=&#x02009;cognitive behavioural treatment, TAU&#x02009;=&#x02009;treatment as usual, HFRS&#x02009;=&#x02009;Hot Flush Rating Scale</p></caption><graphic id="nlm-graphic-1" xlink:href="PON-24-1159-g001"/></fig><p>At a second assessment interview 6&#x000a0;weeks later (with OY) (post&#x02010;treatment), participants completed questionnaires, reported any health or medication changes in the previous 6&#x000a0;weeks and wore the SSC monitor again for 48&#x000a0;h. At 32&#x000a0;weeks after randomisation (6&#x000a0;months follow&#x02010;up), postal questionnaires were completed. At the end of the study, TAU participants were offered the guided self&#x02010;help CBT off trial.</p><p>Randomisation and blinding: Computer software (Rand.exe version 6) was used to assign men randomly to the CBT or TAU groups, stratifying for cancer type (i.e. local or locally advanced vs. metastatic). A researcher (OY) generated the randomised allocation list in sealed envelopes at the beginning of the trial. The patients and the clinical psychologist (ES) could not be blind to group allocation; however, the researcher (OY) remained blind to group allocation throughout the trial, carried out 6&#x02010;week and 32&#x02010;week assessments and performed all data entry. To check whether the researcher was successfully masked, he estimated which group participants had been allocated to after the post&#x02010;treatment assessment. Masking was reasonably successful with the allocation of 61% being correctly identified and equal proportions from CBT and TAU groups. An independent researcher (EG), also masked to group allocations, performed the statistical analyses.</p><p>The intervention: The guided self&#x02010;help CBT treatment, based on interventions developed by Hunter and colleagues <xref rid="pon3794-bib-0012" ref-type="ref">12</xref>, <xref rid="pon3794-bib-0013" ref-type="ref">13</xref>, <xref rid="pon3794-bib-0022" ref-type="ref">22</xref>, <xref rid="pon3794-bib-0023" ref-type="ref">23</xref>, is a 4&#x02010;week intervention consisting of a booklet <xref rid="pon3794-bib-0020" ref-type="ref">20</xref> containing:
<list list-type="roman-lower" id="pon3794-list-0001"><list-item id="pon3794-li-0001"><p>information about causes of HFNS, the CBT model and factors affecting HFNS, such as modifying triggers, e.g. caffeine (Week 1),</p></list-item><list-item id="pon3794-li-0002"><p>cognitive therapy for overly negative thoughts and beliefs about HFNS, and behavioural strategies, e.g. using paced breathing and relaxation, to reduce stress and manage HFNS (Week 2),</p></list-item><list-item id="pon3794-li-0003"><p>CBT strategies for managing sleep and NS (Week 3),</p></list-item><list-item id="pon3794-li-0004"><p>suggestions for maintaining changes in the context of prostate cancer (Week 4).</p></list-item></list>
</p><p>The intervention which was effective for women with HFNS was adapted for men, being informed by a qualitative study <xref rid="pon3794-bib-0024" ref-type="ref">24</xref>, and was piloted on 12 prostate cancer survivors who provided feedback on content and how much guidance they required, for example the term &#x02018;hot sweats&#x02019; was preferred to &#x02018;hot flushes&#x02019;.</p><p>At the end of the assessment those randomised to CBT were given the booklet and a CD with relaxation/paced breathing exercises by a clinical psychologist (ES). Guiding consisted of a telephone call (average 30&#x000a0;min; range 20&#x02013;40&#x000a0;min) from the clinical psychologist 2&#x000a0;weeks into treatment to provide support and discuss individual goals and progress. TAU included access to clinical staff, and cancer information and support services, which provided information and advice about HFNS.</p></sec><sec id="pon3794-sec-0009"><title>Measures</title><p>Sociodemographic and clinical information were obtained from baseline questionnaires and the clinical interview. Health economics questions, adapted from Beecham &#x00026; Knapp <xref rid="pon3794-bib-0025" ref-type="ref">25</xref>, included number of consultations at primary and secondary care and treatments used at post&#x02010;treatment and follow&#x02010;up.</p><p>Primary outcome was HFNS problem&#x02010;rating at 6&#x000a0;weeks post&#x02010;randomisation using the Hot Flush Rating Scale (HFRS) <xref rid="pon3794-bib-0021" ref-type="ref">21</xref>; problem&#x02010;rating or interference is associated with help&#x02010;seeking and quality of life <xref rid="pon3794-bib-0017" ref-type="ref">17</xref> and is recommended as the most appropriate outcome measure in clinical trials <xref rid="pon3794-bib-0018" ref-type="ref">18</xref>. HFNS problem&#x02010;rating score is the mean of three items (assessing the extent to which flushes are problematic, distressing and interfere with daily life) rated on 10&#x02010;point scales where higher scores indicate more bothersome HFNS. A change of 2 points is considered clinically relevant in studies of women <xref rid="pon3794-bib-0012" ref-type="ref">12</xref>, <xref rid="pon3794-bib-0013" ref-type="ref">13</xref>. At baseline, internal consistency was high (Cronbach alpha&#x02009;=&#x02009;0.87).</p><p>Secondary outcomes included: HFNS problem&#x02010;rating (HFRS) at 32&#x000a0;weeks; depression and anxiety, as assessed by the Hospital Anxiety and Depression Scale (HADS) <xref rid="pon3794-bib-0026" ref-type="ref">26</xref>; HFNS weekly frequency in the past week, as assessed by the HFRS <xref rid="pon3794-bib-0021" ref-type="ref">21</xref>; quality of life using the EORTC QLQ&#x02010;C30 <xref rid="pon3794-bib-0027" ref-type="ref">27</xref> and the EORTC QLQ&#x02010;PR25 <xref rid="pon3794-bib-0028" ref-type="ref">28</xref> prostate cancer&#x02010;specific measure at 6 and 32&#x000a0;weeks.</p><p>Possible moderators included age, marital status, level of education, ethnicity, cancer type, BMI, as well as the Constructed Meaning Scale (CMS) <xref rid="pon3794-bib-0029" ref-type="ref">29</xref>, the Emotional Control subscale of the Barriers to Help Seeking Scale <xref rid="pon3794-bib-0030" ref-type="ref">30</xref>, the Somatosensory Amplification Scale <xref rid="pon3794-bib-0031" ref-type="ref">31</xref> and Revised Life Orientation Test (LOT&#x02010;R) <xref rid="pon3794-bib-0032" ref-type="ref">32</xref>. Potential mediators included the Hot Flush Beliefs and Behaviour Scale&#x02010;for Men scale (HFBBS), developed to assess men's cognitive appraisals (beliefs) and behaviours in relation to their HFNS <xref rid="pon3794-bib-0033" ref-type="ref">33</xref> with three subscales (Negative HFNS beliefs/behaviours, Calm acceptance and Humour/openness, scored 1&#x02013;6) and frequency of HFNS using 48&#x02010;h ambulatory SSC monitoring <xref rid="pon3794-bib-0019" ref-type="ref">19</xref>, <xref rid="pon3794-bib-0034" ref-type="ref">34</xref>, <xref rid="pon3794-bib-0035" ref-type="ref">35</xref>. Questions about self&#x02010;efficacy and treatment expectations were asked prior to randomisation.</p><p>Adherence to CBT was measured by the number of booklet chapters read and the number of times relaxation/paced breathing were practised each week, recorded at the end of treatment. Adverse events were recorded in both groups.</p></sec><sec id="pon3794-sec-0010"><title>Statistical analysis</title><p>A total sample size of 50 (25 in each group) was needed to provide 90% power to detect a clinically significant difference in mean HFNS problem rating of 2 points, for the comparison of CBT to TAU at 6&#x000a0;weeks post&#x02010;randomisation, allowing for baseline value (estimated to have a mean of 5 and SD of 2.4) and a HFNS problem rating baseline&#x02010;to&#x02010;outcome correlation of 0.4 on analysis of covariance with two&#x02010;sided 5% significance levels. Analyses were conducted on a modified intention&#x02010;to&#x02010;treat basis; missing values were replaced by the average scores of completed items, in the same scale for each individual, provided that at least 50% of the items in that scale had been completed. Analyses of covariance were carried out for each variable separately, comparing baseline scores with (a) 6&#x02010;week and (b) 32&#x02010;week scores, with group (CBT vs. TAU) as fixed factor and baseline scores as covariates and Bonferroni adjustment for multiple comparisons. Statistical analyses are reported with adjusted mean differences (standard errors; SE), and two&#x02010;sided 95% CIs. SPSS (version 18.0) was used for all statistical analyses.</p></sec></sec><sec id="pon3794-sec-0011"><title>Results</title><p>One hundred and fifteen men expressed interest in the study and 68 met inclusion criteria and were randomised (Figure <xref rid="pon3794-fig-0001" ref-type="fig">1</xref>). Withdrawal rates were minimal at 6&#x000a0;weeks, and complete data were available for 66 participants for the primary outcome measure (HFNS problem&#x02010;rating). Baseline demographics and clinical characteristics were broadly similar in both treatment groups (Table <xref rid="pon3794-tbl-0001" ref-type="table-wrap">1</xref>). The sample had a mean age of 69&#x000a0;years, range 49 to 83&#x000a0;years. They tended to be mainly of white ethnicity (74%), married/cohabiting (74%), unemployed/retired (78%) and 48% of men had received education beyond 16&#x000a0;years. Comorbidity was common; additional medical conditions included cardiovascular (e.g. high blood pressure 44.2%), haematological (e.g. cholesterol, diabetes 32.6%) or musculoskeletal (e.g. joint pain 16.3%) problems. Cancer diagnosis included localised (50%), locally advanced (19%) and metastatic cancer (31%) (Table <xref rid="pon3794-tbl-0001" ref-type="table-wrap">1</xref>). On average the men had been on their current ADT regime for 16&#x000a0;months (range 2&#x02013;74&#x000a0;months). Baseline anxiety and depression scores (HADs) were 5.17 (SD&#x02009;=&#x02009;5.17) and 4.10 (4.10), respectively (25% scored above the cut&#x02010;off for depression and 20.6% for anxiety) and Global QOL (EORTC) was 69.19 (SD&#x02009;=&#x02009;17.23).</p><table-wrap id="pon3794-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and clinical baseline characteristics (<italic>N</italic> (%) or mean (SD) with <italic>p</italic> values for between group comparisons)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th id="pon3794-ent-0001" align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" id="pon3794-ent-0002" valign="bottom" rowspan="1" colspan="1">CBT (<italic>n</italic>&#x02009;=&#x02009;33)</th><th align="center" id="pon3794-ent-0003" valign="bottom" rowspan="1" colspan="1">TAU (<italic>n</italic>&#x02009;=&#x02009;35)</th><th align="center" id="pon3794-ent-0004" valign="bottom" rowspan="1" colspan="1">
<italic>p</italic> Values</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at randomisation [years]</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">67.97&#x02009;(7.65)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">69.71&#x02009;(7.90)</td><td align="char" char="." id="pon3794-ent-0008" valign="top" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ethnic origin</td><td align="left" id="pon3794-ent-0010" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0011" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0012" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" valign="top" rowspan="1" colspan="1">White</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">28&#x02009;(85%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">22&#x02009;(63%)</td><td align="char" char="." id="pon3794-ent-0016" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="right" valign="top" rowspan="1" colspan="1">Black</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5&#x02009;(15%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12&#x02009;(34%)</td><td id="pon3794-ent-0020" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" valign="top" rowspan="1" colspan="1">Other</td><td align="left" id="pon3794-ent-0022" valign="top" rowspan="1" colspan="1"/><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#x02009;(3%)</td><td id="pon3794-ent-0024" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Married/living with partner</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25&#x02009;(76%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25&#x02009;(71%)</td><td align="char" char="." id="pon3794-ent-0028" valign="top" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Educated beyond 16&#x000a0;years of age</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16&#x02009;(49%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16&#x02009;(46%)</td><td align="char" char="." id="pon3794-ent-0032" valign="top" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employed</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9&#x02009;(27%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6&#x02009;(17%)</td><td align="char" char="." id="pon3794-ent-0036" valign="top" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean body mass index (kg/m<sup>2</sup>; SD)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">26.40&#x02009;(3.79)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27.74&#x02009;(3.63)</td><td align="char" char="." id="pon3794-ent-0040" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cancer type</td><td align="left" id="pon3794-ent-0042" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0043" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0044" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0045" valign="top" rowspan="1" colspan="1">Localised</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16&#x02009;(49%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18&#x02009;(51.5%)</td><td align="char" char="." id="pon3794-ent-0048" valign="top" rowspan="1" colspan="1">0.91</td></tr><tr><td align="right" id="pon3794-ent-0049" valign="top" rowspan="1" colspan="1">Locally advanced</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">7&#x02009;(21%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6&#x02009;(17%)</td><td id="pon3794-ent-0052" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0053" valign="top" rowspan="1" colspan="1">Metastatic</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10&#x02009;(30%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11&#x02009;(31.5%)</td><td id="pon3794-ent-0056" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0057" align="left" valign="top" rowspan="1" colspan="1">Time since prostate cancer diagnosis [months]</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">24.76&#x02009;(20.70)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.57&#x02009;(34.48)</td><td align="char" char="." id="pon3794-ent-0060" valign="top" rowspan="1" colspan="1">0.49</td></tr><tr><td id="pon3794-ent-0061" align="left" valign="top" rowspan="1" colspan="1">Previous treatment history:</td><td align="left" id="pon3794-ent-0062" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0063" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0064" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0065" valign="top" rowspan="1" colspan="1">Prostatectomy</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10&#x02009;(30%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">8&#x02009;(23%)</td><td align="char" char="." id="pon3794-ent-0068" valign="top" rowspan="1" colspan="1">0.49</td></tr><tr><td align="right" id="pon3794-ent-0069" valign="top" rowspan="1" colspan="1">Radiotherapy</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">23&#x02009;(70%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18&#x02009;(51%)</td><td align="char" char="." id="pon3794-ent-0072" valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td id="pon3794-ent-0073" align="left" valign="top" rowspan="1" colspan="1">Current hormonal therapy:</td><td align="left" id="pon3794-ent-0074" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0075" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0076" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0077" align="left" valign="top" rowspan="1" colspan="1">Luteinizing/gonadotropin&#x02010;releasing hormone agonists</td><td align="left" id="pon3794-ent-0078" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0079" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0080" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0081" valign="top" rowspan="1" colspan="1">Goserelin (zoladex)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">23&#x02009;(70%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">23&#x02009;(66%)</td><td id="pon3794-ent-0084" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0085" valign="top" rowspan="1" colspan="1">Leupropelin (prostap)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#x02009;(6%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5&#x02009;(14%)</td><td id="pon3794-ent-0088" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0089" valign="top" rowspan="1" colspan="1">Triptorelin (de&#x02010;capeptyl)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#x02009;(6%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2&#x02009;(6%)</td><td id="pon3794-ent-0092" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0093" align="left" valign="top" rowspan="1" colspan="1">Anti&#x02010;androgens</td><td align="left" id="pon3794-ent-0094" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0095" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0096" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0097" valign="top" rowspan="1" colspan="1">Cyproterone acetate (cyprostat)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#x02009;(3%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td id="pon3794-ent-0100" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0101" valign="top" rowspan="1" colspan="1">Bicalutamide (Casodex)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5&#x02009;(15%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5&#x02009;(14%)</td><td id="pon3794-ent-0104" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0105" align="left" valign="top" rowspan="1" colspan="1">Receiving other treatments for HFNS at baseline:</td><td align="left" id="pon3794-ent-0106" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0107" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0108" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0109" valign="top" rowspan="1" colspan="1">Red clover</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3&#x02009;(9%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#x02009;(3%)</td><td id="pon3794-ent-0112" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0113" valign="top" rowspan="1" colspan="1">Fish oils</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#x02009;(3%)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td id="pon3794-ent-0116" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0117" valign="top" rowspan="1" colspan="1">Ginseng</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#x02009;(3%)</td><td id="pon3794-ent-0120" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="right" id="pon3794-ent-0121" valign="top" rowspan="1" colspan="1">Evening primrose</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">0</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1&#x02009;(3%)</td><td id="pon3794-ent-0124" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0125" align="left" valign="top" rowspan="1" colspan="1">Self&#x02010;efficacy in carrying out treatment</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.51&#x02009;(1.08)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.40&#x02009;(0.93)</td><td align="char" char="." id="pon3794-ent-0128" valign="top" rowspan="1" colspan="1">0.20</td></tr><tr><td id="pon3794-ent-0129" align="left" valign="top" rowspan="1" colspan="1">Treatment expectations</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.09&#x02009;(1.19)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.05&#x02009;(0.82)</td><td align="char" char="." id="pon3794-ent-0132" valign="top" rowspan="1" colspan="1">0.18</td></tr><tr><td id="pon3794-ent-0133" align="left" valign="top" rowspan="1" colspan="1">Somatosensory Amplification Scale</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.47&#x02009;(0.60)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.47&#x02009;(0.59)</td><td align="char" char="." id="pon3794-ent-0136" valign="top" rowspan="1" colspan="1">0.99</td></tr><tr><td id="pon3794-ent-0137" align="left" valign="top" rowspan="1" colspan="1">Revised Life Orientation Test</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">15.96&#x02009;(4.14)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16.05&#x02009;(4.18)</td><td align="char" char="." id="pon3794-ent-0140" valign="top" rowspan="1" colspan="1">0.91</td></tr><tr><td id="pon3794-ent-0141" align="left" valign="top" rowspan="1" colspan="1">Constructed Meaning Scale</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">32.18&#x02009;(6.46)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31.48&#x02009;(6.29)</td><td align="char" char="." id="pon3794-ent-0144" valign="top" rowspan="1" colspan="1">0.65</td></tr><tr><td id="pon3794-ent-0145" align="left" valign="top" rowspan="1" colspan="1">Emotional Control&#x02014;Barriers to Help Seeking Scale</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.71&#x02009;(0.76)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.10&#x02009;(0.82)</td><td align="char" char="." id="pon3794-ent-0148" valign="top" rowspan="1" colspan="1">0.06</td></tr></tbody></table></table-wrap><p>At baseline HFNS were frequent with a weekly average of 54.47 (SD&#x02009;=&#x02009;41.34), range 9 to 280, average duration of 4 (range 2 to 10) min and were rated as moderately problematic, with average scores of 4.68/10 (SD&#x02009;=&#x02009;2.20).</p><sec id="pon3794-sec-0012"><title>Primary outcome</title><p>There was a significant difference between groups in the primary outcome, HFNS problem rating, at 6&#x000a0;weeks after randomisation (adjusted mean difference of &#x02212;1.33, 95% CI &#x02212;2.07 to &#x02212;0.58; <italic>p</italic>&#x02009;=&#x02009;0.001) with a greater reduction from baseline in the CBT group compared to the TAU group and a large effect size (Table <xref rid="pon3794-tbl-0002" ref-type="table-wrap">2</xref>, Figure <xref rid="pon3794-fig-0002" ref-type="fig">2</xref>). The change in problem rating from baseline was &#x02212;1.81 (SD 1.94) in the CBT group, compared with &#x02212;0.57 (SD 1.74) in TAU group, representing to a 40% reduction in the CBT group and a 12% reduction in the TAU group; 41% of the CBT group had a two&#x02010;point reduction in HFNS problem rating compared to 23% of those allocated to TAU.</p><table-wrap id="pon3794-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Effect of treatment on hot flushes and night sweats measures: HFNS problem rating, frequency and Beliefs and Behaviours Scale; HADs and Global QOL (EORTC). SSC&#x02009;=&#x02009;Sternal Skin Conductance</p></caption><table frame="hsides" rules="groups"><col align="right" span="1"/><col align="char" char="(" span="1"/><col align="center" span="1"/><col align="char" char="(" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" id="pon3794-ent-0149" valign="bottom" rowspan="1" colspan="1"/><th align="center" id="pon3794-ent-0150" valign="bottom" rowspan="1" colspan="1">CBT mean (SD)</th><th id="pon3794-ent-0151" align="center" valign="bottom" rowspan="1" colspan="1">
<italic>N</italic>
</th><th align="center" id="pon3794-ent-0152" valign="bottom" rowspan="1" colspan="1">TAU mean (SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>N</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adjusted mean difference (SE)</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="pon3794-ent-0156" valign="bottom" rowspan="1" colspan="1">HFNS problem rating</th><th align="left" id="pon3794-ent-0157" valign="bottom" rowspan="1" colspan="1"/><th align="left" id="pon3794-ent-0158" valign="bottom" rowspan="1" colspan="1"/><th align="left" id="pon3794-ent-0159" valign="bottom" rowspan="1" colspan="1"/><th align="left" id="pon3794-ent-0160" valign="bottom" rowspan="1" colspan="1"/><th id="pon3794-ent-0161" align="left" valign="bottom" rowspan="1" colspan="1"/><th id="pon3794-ent-0162" align="left" valign="bottom" rowspan="1" colspan="1"/></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.54&#x02009;(1.98)</td><td id="pon3794-ent-0165" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.81&#x02009;(2.41)</td><td id="pon3794-ent-0167" align="center" valign="top" rowspan="1" colspan="1">35</td><td id="pon3794-ent-0168" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0169" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0170" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.76&#x02009;(1.53)</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.19&#x02009;(2.20)</td><td id="pon3794-ent-0174" align="center" valign="top" rowspan="1" colspan="1">34</td><td align="char" char="(" id="pon3794-ent-0175" valign="top" rowspan="1" colspan="1">&#x02212;1.33&#x02009;(0.37)<xref ref-type="fn" rid="pon3794-note-0004">**</xref> Effect size partial Eta<sup>2</sup>&#x02009;=&#x02009;0.16</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;2.07&#x000a0;to&#x02009;&#x02212;0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.66&#x02009;(1.67)</td><td id="pon3794-ent-0179" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.33&#x02009;(1.84)</td><td id="pon3794-ent-0181" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" id="pon3794-ent-0182" valign="top" rowspan="1" colspan="1">&#x02212;0.7&#x02009;(0.43)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;1.59&#x000a0;to&#x000a0;0.16</td></tr><tr><td align="left" id="pon3794-ent-0184" valign="top" rowspan="1" colspan="1">HFNS total frequency</td><td align="left" id="pon3794-ent-0185" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0186" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0187" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0188" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0189" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0190" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0191" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">56.09&#x02009;(30.16)</td><td id="pon3794-ent-0193" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">52.95&#x02009;(50.07)</td><td id="pon3794-ent-0195" align="center" valign="top" rowspan="1" colspan="1">35</td><td id="pon3794-ent-0196" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0197" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0198" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">36.06&#x02009;(25.03)</td><td id="pon3794-ent-0200" align="center" valign="top" rowspan="1" colspan="1">32</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">44.58&#x02009;(38.70)</td><td id="pon3794-ent-0202" align="center" valign="top" rowspan="1" colspan="1">34</td><td align="char" char="(" id="pon3794-ent-0203" valign="top" rowspan="1" colspan="1">&#x02212;12.12&#x02009;(5.14)<xref ref-type="fn" rid="pon3794-note-0003">*</xref> Effect size partial Eta<sup>2</sup>&#x02009;=&#x02009;0.08</td><td align="char" char="&#x02212;" id="pon3794-ent-0204" valign="top" rowspan="1" colspan="1">&#x02212;22.39&#x000a0;to&#x02009;&#x02212;1.84</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">32.11&#x02009;(24.54)</td><td id="pon3794-ent-0207" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">42.08&#x02009;(54.85)</td><td id="pon3794-ent-0209" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" id="pon3794-ent-0210" valign="top" rowspan="1" colspan="1">&#x02212;12.43&#x02009;(7.93)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;28.38&#x000a0;to&#x000a0;3.52</td></tr><tr><td align="left" id="pon3794-ent-0212" valign="top" rowspan="1" colspan="1">HF frequency</td><td align="left" id="pon3794-ent-0213" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0214" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0215" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0216" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0217" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0218" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0219" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">39.18&#x02009;(24.21)</td><td id="pon3794-ent-0221" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">34.94&#x02009;(39.56)</td><td id="pon3794-ent-0223" align="center" valign="top" rowspan="1" colspan="1">35</td><td id="pon3794-ent-0224" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0225" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0226" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25.56&#x02009;(18.63)</td><td id="pon3794-ent-0228" align="center" valign="top" rowspan="1" colspan="1">32</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27.47&#x02009;(23.74)</td><td id="pon3794-ent-0230" align="center" valign="top" rowspan="1" colspan="1">34</td><td align="char" char="(" id="pon3794-ent-0231" valign="top" rowspan="1" colspan="1">&#x02212;4.97&#x02009;(4.06)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;13.09&#x000a0;to&#x000a0;3.14</td></tr><tr><td id="pon3794-ent-0233" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">19.40&#x02009;(17.93)</td><td id="pon3794-ent-0235" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.95&#x02009;(39.63)</td><td id="pon3794-ent-0237" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" id="pon3794-ent-0238" valign="top" rowspan="1" colspan="1">&#x02212;12.80&#x02009;(6.17)<xref ref-type="fn" rid="pon3794-note-0003">*</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;25.21&#x000a0;to&#x02009;&#x02212;3.86</td></tr><tr><td align="left" id="pon3794-ent-0240" valign="top" rowspan="1" colspan="1">NS frequency</td><td align="left" id="pon3794-ent-0241" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0242" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0243" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0244" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0245" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0246" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0247" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16.90&#x02009;(14.27)</td><td id="pon3794-ent-0249" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18.01&#x02009;(13.05)</td><td id="pon3794-ent-0251" align="center" valign="top" rowspan="1" colspan="1">35</td><td id="pon3794-ent-0252" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0253" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0254" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">10.50&#x02009;(9.67)</td><td id="pon3794-ent-0256" align="center" valign="top" rowspan="1" colspan="1">32</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">17.11&#x02009;(18.80)</td><td id="pon3794-ent-0258" align="center" valign="top" rowspan="1" colspan="1">34</td><td align="char" char="(" id="pon3794-ent-0259" valign="top" rowspan="1" colspan="1">&#x02212;5.79&#x02009;(2.96)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;11.71&#x000a0;to&#x000a0;0.13</td></tr><tr><td id="pon3794-ent-0261" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12.70&#x02009;(11.72)</td><td id="pon3794-ent-0263" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12.12&#x02009;(17.67)</td><td id="pon3794-ent-0265" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" id="pon3794-ent-0266" valign="top" rowspan="1" colspan="1">0.66&#x02009;(3.59)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;6.56&#x000a0;to&#x000a0;7.88</td></tr><tr><td align="left" id="pon3794-ent-0268" valign="top" rowspan="1" colspan="1">SSC frequency</td><td align="left" id="pon3794-ent-0269" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0270" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0271" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0272" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0273" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0274" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0275" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">29.31&#x02009;(11.73)</td><td id="pon3794-ent-0277" align="center" valign="top" rowspan="1" colspan="1">23</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27.80&#x02009;(11.63)</td><td id="pon3794-ent-0279" align="center" valign="top" rowspan="1" colspan="1">21</td><td id="pon3794-ent-0280" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0281" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0282" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">27.47&#x02009;(9.99)</td><td id="pon3794-ent-0284" align="center" valign="top" rowspan="1" colspan="1">20</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">23.61&#x02009;(11.98)</td><td id="pon3794-ent-0286" align="center" valign="top" rowspan="1" colspan="1">12</td><td align="char" char="(" id="pon3794-ent-0287" valign="top" rowspan="1" colspan="1">0.69&#x02009;(3.19)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5.84&#x000a0;to&#x02009;&#x02212;7.22</td></tr><tr><td align="left" id="pon3794-ent-0289" valign="top" rowspan="1" colspan="1">HF beliefs/behaviour</td><td align="left" id="pon3794-ent-0290" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0291" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0292" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0293" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0294" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0295" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0296" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.06&#x02009;(1.00)</td><td id="pon3794-ent-0298" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.06&#x02009;(1.18)</td><td id="pon3794-ent-0300" align="center" valign="top" rowspan="1" colspan="1">33</td><td id="pon3794-ent-0301" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0302" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0303" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.41&#x02009;(1.08)</td><td id="pon3794-ent-0305" align="center" valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.35&#x02009;(1.12)</td><td id="pon3794-ent-0307" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" id="pon3794-ent-0308" valign="top" rowspan="1" colspan="1">&#x02212;0.92&#x02009;(0.20)<xref ref-type="fn" rid="pon3794-note-0004">**</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;1.34&#x000a0;to&#x02009;&#x02212;0.51</td></tr><tr><td id="pon3794-ent-0310" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">1.57&#x02009;(1.17)</td><td id="pon3794-ent-0312" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.09&#x02009;(0.98)</td><td id="pon3794-ent-0314" align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" id="pon3794-ent-0315" valign="top" rowspan="1" colspan="1">&#x02212;0.49&#x02009;(0.30)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;1.11&#x000a0;to&#x000a0;0.12</td></tr><tr><td align="left" id="pon3794-ent-0317" valign="top" rowspan="1" colspan="1">Calm acceptance</td><td align="left" id="pon3794-ent-0318" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0319" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0320" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0321" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0322" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0323" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0324" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.62&#x02009;(0.78)</td><td id="pon3794-ent-0326" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">2.75&#x02009;(0.97)</td><td id="pon3794-ent-0328" align="center" valign="top" rowspan="1" colspan="1">33</td><td id="pon3794-ent-0329" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0330" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0331" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.58&#x02009;(1.11)</td><td id="pon3794-ent-0333" align="center" valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.81&#x02009;(0.90)</td><td id="pon3794-ent-0335" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" id="pon3794-ent-0336" valign="top" rowspan="1" colspan="1">&#x02212;0.29&#x02009;(0.16)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.70&#x000a0;to&#x000a0;0.21</td></tr><tr><td id="pon3794-ent-0338" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.09&#x02009;(0.67)</td><td id="pon3794-ent-0340" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.90&#x02009;(0.49)</td><td id="pon3794-ent-0342" align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" id="pon3794-ent-0343" valign="top" rowspan="1" colspan="1">0.29&#x02009;(0.18)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.07&#x000a0;to&#x000a0;0.66</td></tr><tr><td align="left" id="pon3794-ent-0345" valign="top" rowspan="1" colspan="1">Humour openness</td><td align="left" id="pon3794-ent-0346" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0347" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0348" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0349" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0350" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0351" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0352" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.22&#x02009;(1.04)</td><td id="pon3794-ent-0354" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.07&#x02009;(1.37)</td><td id="pon3794-ent-0356" align="center" valign="top" rowspan="1" colspan="1">33</td><td id="pon3794-ent-0357" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0358" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0359" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.58&#x02009;(1.17)</td><td id="pon3794-ent-0361" align="center" valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.02&#x02009;(0.91)</td><td id="pon3794-ent-0363" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" id="pon3794-ent-0364" valign="top" rowspan="1" colspan="1">0.56&#x02009;(0.23)<xref ref-type="fn" rid="pon3794-note-0003">*</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.10&#x000a0;to&#x000a0;1.01</td></tr><tr><td id="pon3794-ent-0366" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.55&#x02009;(1.05)</td><td id="pon3794-ent-0368" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.52&#x02009;(0.80)</td><td id="pon3794-ent-0370" align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" id="pon3794-ent-0371" valign="top" rowspan="1" colspan="1">0.20&#x02009;(0.25)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;0.31&#x000a0;to&#x000a0;0.72</td></tr><tr><td align="left" id="pon3794-ent-0373" valign="top" rowspan="1" colspan="1">HADS depression</td><td align="left" id="pon3794-ent-0374" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0375" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0376" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0377" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0378" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0379" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0380" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.03&#x02009;(3.57)</td><td id="pon3794-ent-0382" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.17&#x02009;(3.27)</td><td id="pon3794-ent-0384" align="center" valign="top" rowspan="1" colspan="1">33</td><td id="pon3794-ent-0385" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0386" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0387" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.26&#x02009;(3.40)</td><td id="pon3794-ent-0389" align="center" valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.21&#x02009;(3.46)</td><td id="pon3794-ent-0391" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" id="pon3794-ent-0392" valign="top" rowspan="1" colspan="1">&#x02212;0.59&#x02009;(0.67)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;1.94&#x000a0;to&#x000a0;0.74</td></tr><tr><td id="pon3794-ent-0394" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.61&#x02009;(3.11)</td><td id="pon3794-ent-0396" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">3.16&#x02009;(2.22)</td><td id="pon3794-ent-0398" align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" id="pon3794-ent-0399" valign="top" rowspan="1" colspan="1">&#x02212;0.52&#x02009;(0.83)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;1.15&#x000a0;to&#x000a0;2.20</td></tr><tr><td align="left" id="pon3794-ent-0401" valign="top" rowspan="1" colspan="1">HADS anxiety</td><td align="left" id="pon3794-ent-0402" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0403" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0404" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0405" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0406" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0407" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0408" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.06&#x02009;(2.96)</td><td id="pon3794-ent-0410" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.28&#x02009;(3.64)</td><td id="pon3794-ent-0412" align="center" valign="top" rowspan="1" colspan="1">33</td><td id="pon3794-ent-0413" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0414" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0415" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.70&#x02009;(3.33)</td><td id="pon3794-ent-0417" align="center" valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.14&#x02009;(4.09)</td><td id="pon3794-ent-0419" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" id="pon3794-ent-0420" valign="top" rowspan="1" colspan="1">&#x02212;0.15&#x02009;(0.68)</td><td align="char" char="&#x02212;" id="pon3794-ent-0421" valign="top" rowspan="1" colspan="1">&#x02212;1.21&#x000a0;to&#x000a0;1.52</td></tr><tr><td id="pon3794-ent-0422" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.15&#x02009;(2.73)</td><td id="pon3794-ent-0424" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.83&#x02009;(2.81)</td><td id="pon3794-ent-0426" align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" id="pon3794-ent-0427" valign="top" rowspan="1" colspan="1">&#x02212;0.32&#x02009;(0.70)</td><td align="char" char="&#x02212;" id="pon3794-ent-0428" valign="top" rowspan="1" colspan="1">&#x02212;1.75&#x000a0;to&#x000a0;1.10</td></tr><tr><td align="left" id="pon3794-ent-0429" valign="top" rowspan="1" colspan="1">EORTC global QOL</td><td align="left" id="pon3794-ent-0430" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0431" align="center" valign="top" rowspan="1" colspan="1"/><td align="left" id="pon3794-ent-0432" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0433" align="center" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0434" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0435" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0436" align="left" valign="top" rowspan="1" colspan="1">Baseline</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">72.22&#x02009;(17.26)</td><td id="pon3794-ent-0438" align="center" valign="top" rowspan="1" colspan="1">33</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">66.16&#x02009;(16.92)</td><td id="pon3794-ent-0440" align="center" valign="top" rowspan="1" colspan="1">33</td><td id="pon3794-ent-0441" align="left" valign="top" rowspan="1" colspan="1"/><td id="pon3794-ent-0442" align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td id="pon3794-ent-0443" align="left" valign="top" rowspan="1" colspan="1">6&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">76.19&#x02009;(20.12)</td><td id="pon3794-ent-0445" align="center" valign="top" rowspan="1" colspan="1">30</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">68.26&#x02009;(19.15)</td><td id="pon3794-ent-0447" align="center" valign="top" rowspan="1" colspan="1">27</td><td align="char" char="(" id="pon3794-ent-0448" valign="top" rowspan="1" colspan="1">3.61&#x02009;(4.49)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;5.42&#x000a0;to&#x000a0;12.63</td></tr><tr><td id="pon3794-ent-0450" align="left" valign="top" rowspan="1" colspan="1">32&#x000a0;weeks</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">75.36&#x02009;(18.54)</td><td id="pon3794-ent-0452" align="center" valign="top" rowspan="1" colspan="1">24</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">70.83&#x02009;(17.59)</td><td id="pon3794-ent-0454" align="center" valign="top" rowspan="1" colspan="1">17</td><td align="char" char="(" id="pon3794-ent-0455" valign="top" rowspan="1" colspan="1">&#x02212;0.97&#x02009;(5.91)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">&#x02212;13.01&#x000a0;to&#x000a0;11.01</td></tr></tbody></table><table-wrap-foot><fn id="pon3794-note-0001"><p>CBT&#x02009;=&#x02009;Cognitive Behavioural Therapy</p></fn><fn id="pon3794-note-0002"><p>TAU&#x02009;=&#x02009;Treatment as usual</p></fn><fn id="pon3794-note-0003"><label>*</label><p>
<italic>p</italic>&#x02009;=&#x02009;0.05.</p></fn><fn id="pon3794-note-0004"><label>**</label><p>
<italic>p</italic>&#x02009;=&#x02009;0.001.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="pon3794-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes in problem rating scores for hot flushes and night sweats in CBT and TAU groups from baseline to 6 and 32&#x000a0;weeks post randomisation. Error bars show 95% CI</p></caption><graphic id="nlm-graphic-3" xlink:href="PON-24-1159-g002"/></fig></sec><sec id="pon3794-sec-0013"><title>Secondary outcomes</title><p>There was a significant difference between groups in HFNS frequency at 6&#x000a0;weeks (adjusted mean difference &#x02212;12.12, 95% CI &#x02212;22.39 to &#x02212;1.84; <italic>p</italic>&#x02009;=&#x02009;0.02) with greater reductions from baseline in the CBT group compared to the TAU group (Figure <xref rid="pon3794-fig-0003" ref-type="fig">3</xref>), with a 36% reduction in the CBT group and 16% for TAU, and a medium effect size (Table <xref rid="pon3794-tbl-0002" ref-type="table-wrap">2</xref>). At 32&#x000a0;weeks the CBT group maintained their improvements in HFNS problem rating (CBT 41% and TAU 31% reductions from baseline) and frequency (CBT 42% and TAU 20% reductions from baseline), but group differences were not significant. When HFNS were considered separately, there were significant group differences in frequency of hot flushes at 32&#x000a0;weeks (Table <xref rid="pon3794-tbl-0002" ref-type="table-wrap">2</xref>). No significant group differences were observed for depressed mood, anxiety (HADS) or quality of life (EORTC QLQ&#x02010;C30 Global QOL) at 6 or 32&#x000a0;weeks (Table <xref rid="pon3794-tbl-0002" ref-type="table-wrap">2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="pon3794-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Changes in frequency for hot flushes and night sweats in CBT and TAU groups from baseline to 6 and 32&#x000a0;weeks post randomisation. Error bars show 95% CIs</p></caption><graphic id="nlm-graphic-5" xlink:href="PON-24-1159-g003"/></fig><p>CBT was more effective than TAU in reducing HFNS problem rating regardless of BMI (normal vs. overweight/obese), educational level (16&#x000a0;years or less vs. more than 16&#x000a0;years) or cancer type (locally and locally advanced vs. metastatic). There were too few numbers in each category to analyse ethnicity (white vs. non&#x02010;white) or marital status. The group difference in the primary outcome, HFNS problem rating at 6&#x000a0;weeks, remained significant (adjusted mean difference of &#x02212;1.38, 95% CI &#x02212;2.16 to &#x02212;0.60; <italic>p</italic>&#x02009;=&#x02009;0.001) when we adjusted for baseline HADs scores, cancer type, age, BMI, educational level and employment. Baseline self&#x02010;efficacy and treatment expectations, CMS, EC, SAS and optimism (LOT&#x02010;R) (Table <xref rid="pon3794-tbl-0001" ref-type="table-wrap">1</xref>) did not moderate HFNS problem&#x02010;rating outcomes at 6&#x000a0;weeks.</p><sec id="pon3794-sec-0014"><title>HFNS beliefs and behaviours</title><p>There were significant group differences in HFNS Beliefs and Behaviour subscales (see Table <xref rid="pon3794-tbl-0002" ref-type="table-wrap">2</xref>), the CBT group reporting less negative HFNS Bel/Beh about hot flushes (adjusted mean difference &#x02212;0.92, 95% CI &#x02212;1.34 to &#x02212;0.51; <italic>p</italic>&#x02009;=&#x02009;0.0001) and more Humour and Openness (0.56, 95% CI 0.10 to 1.01; <italic>p</italic>&#x02009;=&#x02009;0.02) compared to the TAU group 6&#x000a0;weeks after randomisation. Reduction (more than one point difference) in negative HFNS Bel/Beh (adjusted mean difference 1.61 CI 2.49 to 0.73; <italic>p</italic>&#x02009;=&#x02009;0.001) was associated with improvement in HFNS problem rating at 6&#x000a0;weeks. This effect was not significant for Humour and Openness (0.10 CI &#x02212;0.91 to 1.11).</p></sec><sec id="pon3794-sec-0015"><title>SSC monitoring</title><p>Forty&#x02010;four men wore the SSC monitor; at 6&#x000a0;weeks there was little change in 48&#x02010;h rate of HFNS measured by sternal skin conductance, but there was considerable variability in response (Table <xref rid="pon3794-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="pon3794-sec-0016"><title>Treatment adherence was generally good</title><p>The majority (88%) read either all (69%) or more than half of the booklet (19%); 79% used the relaxation CD, and 76% practiced paced breathing, at least once a week. At 6&#x000a0;weeks, a significantly greater reduction in HFNS problem rating was reported by men who read all of the booklet compared to those who read less (adjusted mean difference of 2.78, 95% CI 2.19 to 3.37; <italic>p</italic>&#x02009;=&#x02009;0.01). No significant differences were found between men who practised the relaxation/paced breathing more or less than once a week.</p></sec><sec id="pon3794-sec-0017"><title>Adverse events, medication changes and use of health services</title><p>Two cases of adverse events unrelated to the intervention were reported: one participant passed away before the 32&#x02010;week assessment because of metastatic cancer and another started chemotherapy, and his data was excluded from further analyses. One participant (CBT) stopped zoladex injections after his 6&#x02010;week assessment, and two (TAU) reported changes between baseline and 6&#x000a0;weeks (one started zoladex and one radiation therapy). Between the 6 and 32&#x000a0;weeks, four (CBT) started new medications for prostate cancer (two casodex, one alpharadin and one zytiga). There were no significant group differences in attendance at GP, oncologist or nurse specialist between baseline and 6&#x000a0;weeks or between 6 and 32&#x000a0;weeks.</p></sec></sec></sec><sec id="pon3794-sec-0018"><title>Discussion</title><p>The results of this trial suggest that CBT appears to be a safe and effective intervention to help prostate cancer patients undergoing ADT to manage troublesome HFNS. At post&#x02010;treatment, the CBT group reported less problematic and less frequent HFNS than the TAU group, with clinically relevant reductions. At 32&#x000a0;weeks the CBT group maintained their improvement but group differences did not reach significance, largely because of some improvement in the TAU group. However, the group difference in hot flush (but not night sweat) frequency remained significant at 32&#x000a0;weeks.</p><p>At baseline the sample reported frequent (44&#x02013;58 HFNS per week) and problematic HFNS, at levels consistent with previous studies of prostate cancer survivors having ADT <xref rid="pon3794-bib-0036" ref-type="ref">36</xref>, <xref rid="pon3794-bib-0037" ref-type="ref">37</xref>. The percentage scoring within the clinical range for depression and anxiety (HADS) (&#x0003e;/8) were 20% and 25% respectively, higher than that reported in a recent meta&#x02010;analysis of prevalence of anxiety (15%) and depression (15%) in men undergoing treatment for prostate cancer <xref rid="pon3794-bib-0038" ref-type="ref">38</xref>, which might be because they all had HFNS&#x02014;which are associated with distress <xref rid="pon3794-bib-0007" ref-type="ref">7</xref>. Their QOL EORTC Global scores (69.19, SD&#x02009;=&#x02009;17.23) were similar to norms for men with prostate cancer (68.4, SD&#x02009;=&#x02009;22.2) <xref rid="pon3794-bib-0039" ref-type="ref">39</xref>. The sample was socially mixed (based on level of education), and comorbid health problems were common. Nevertheless, CBT was effective adjusting for baseline characteristics and regardless of BMI, educational level or cancer type. However, the intervention did not significantly reduce mood or QOL.</p><p>Adherence to the CBT was good in terms of reading the booklet and using the relaxation/paced breathing CD, and those who read the whole booklet derived more benefit. We examined potential mediators in order to understand how the treatment might be working. Although significant improvements in subjective measures were evident, no group differences in physiologically (SSC) measured HFNS were found. The concordance between subjective and physiologically (SSC) measured HFNS is relatively low in ambulatory settings <xref rid="pon3794-bib-0035" ref-type="ref">35</xref>, <xref rid="pon3794-bib-0037" ref-type="ref">37</xref>, but inclusion of SSC measures can aid understanding of how treatments are working. Overall, our results are consistent with findings from a CBT trial for HFNS in breast cancer patients <xref rid="pon3794-bib-0013" ref-type="ref">13</xref>, suggesting that CBT might work mainly by affecting symptom perception and cognitive appraisal of HFNS, rather than physiological mechanisms <xref rid="pon3794-bib-0016" ref-type="ref">16</xref>, <xref rid="pon3794-bib-0023" ref-type="ref">23</xref>, <xref rid="pon3794-bib-0040" ref-type="ref">40</xref>. The CBT group reported less negative HFNS beliefs and behaviours and more humour and openness compared to TAU at 6&#x000a0;weeks, and change in HFNS negative beliefs and behaviours (e.g. changes in beliefs about the social consequences and about sleep, and less avoidance of activities) was associated with reduction in problem&#x02010;rating. Therefore the intervention appeared to be targeting cognitive and behavioural changes as intended.</p><p>Limitations include lack of an attention control arm and the sample size, particularly for the TAU group at 32&#x000a0;weeks; the sample size was not large enough to examine all secondary measures, nor to perform a full mediation analysis. We attempted to reduce bias by masking where possible, but it is not possible to mask participants in this type of trial. Additional variables might have affected HFNS, such as health&#x02010;related behaviours, e.g. caffeine intake, and other specific health problems. Future research could test the intervention in a multi&#x02010;centre trial including a range of ethnicities, as well as examine specific components of the intervention, such as paced breathing.</p><p>In terms of clinical implications, to our knowledge this is the first evaluation of a brief guided self&#x02010;help CBT intervention for men with HFNS. Adherence to treatment was good, and the contact/therapist time was on average only 60&#x000a0;min. The CBT intervention was delivered in a hospital setting, using standardised materials (treatment booklet, CD) and could be included within survivorship support programmes.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="pon3794-supitem-0001"><caption><p>Supporting info item</p></caption><media xlink:href="PON-24-1159-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="pon3794-sec-0019"><title>Acknowledgements</title><p id="pon3794-para-0037">We thank Phil Reynolds, Louisa Fleure, Gian Gargaro. This work was supported by a Prostate Cancer UK Project Award (PG10&#x02010;01).</p></ack><ref-list content-type="cited-references" id="pon3794-bibl-0001"><title>References</title><ref id="pon3794-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="pon3794-cit-0001">
<string-name>
<surname>Jemal</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bray</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Center</surname>
<given-names>MM</given-names>
</string-name>, et al. <article-title>Global cancer statistics</article-title>. <source>CA: A Cancer J Clin</source>
<year>2011</year>;<volume>61</volume>(<issue>2</issue>):<fpage>69</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="pon3794-cit-0002">
<string-name>
<surname>Graham</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Macbeth</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Guidelines: diagnosis and treatment of prostate cancer: summary of NICE guidance</article-title>. <source>BMJ</source>
<year>2008</year>;<volume>336</volume>(<issue>7644</issue>):<fpage>610</fpage>&#x02013;<lpage>612</lpage>.<pub-id pub-id-type="pmid">18340076</pub-id></mixed-citation></ref><ref id="pon3794-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="pon3794-cit-0003">
<string-name>
<surname>Grunfeld</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Halliday</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms</article-title>. <source>Cancer Nurs.</source>
<year>2013</year>;<volume>35</volume>(<issue>1</issue>):<fpage>63</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">21558849</pub-id></mixed-citation></ref><ref id="pon3794-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="pon3794-cit-0004">
<string-name>
<surname>Frisk</surname>
<given-names>J.</given-names>
</string-name>
<article-title>Managing hot flushes in men after prostate cancer. A systematic review</article-title>. <source>Maturitas</source>
<year>2010</year>;<volume>65</volume>(<issue>1</issue>):<fpage>15</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">19962840</pub-id></mixed-citation></ref><ref id="pon3794-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="pon3794-cit-0005">
<string-name>
<surname>Fisher</surname>
<given-names>WI</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Elkins</surname>
<given-names>GR</given-names>
</string-name>, et al. <article-title>Risk factors, pathophysiology, and treatment of hot flashes in cancer</article-title>. <source>CA: A Cancer J Clin</source>
<year>2013</year>;<volume>63</volume>(<issue>3</issue>):<fpage>167</fpage>&#x02013;<lpage>192</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="pon3794-cit-0006">
<string-name>
<surname>Hanisch</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Gooneratne</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Soin</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Sleep and daily functioning during androgen deprivation therapy for prostate cancer</article-title>. <source>Europ J Cancer Care</source>
<year>2011</year>;<volume>20</volume>(<issue>4</issue>):<fpage>549</fpage>&#x02013;<lpage>554</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="pon3794-cit-0007">
<string-name>
<surname>Nishiyama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kanazawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy</article-title>. <source>Intern J Urol</source>
<year>2004</year>;<volume>11</volume>(<issue>9</issue>):<fpage>735</fpage>&#x02013;<lpage>741</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="pon3794-cit-0008">
<string-name>
<surname>Spetz</surname>
<given-names>A&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Zetterlund</surname>
<given-names>E&#x02010;L</given-names>
</string-name>, <string-name>
<surname>Varenhorst</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Incidence and management of hot flashes in prostate cancer</article-title>. <source>J. Support. Oncol.</source>
<year>2001</year>;<volume>1</volume>(<issue>4</issue>):<fpage>263</fpage>&#x02013;<lpage>272</lpage>.<pub-id pub-id-type="pmid">15334868</pub-id></mixed-citation></ref><ref id="pon3794-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="pon3794-cit-0009">
<string-name>
<surname>Ulloa</surname>
<given-names>EW</given-names>
</string-name>, <string-name>
<surname>Salup</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Patterson</surname>
<given-names>SG</given-names>
</string-name>, et al. <article-title>Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer</article-title>. <source>Psycho&#x02010;Oncology</source>
<year>2009</year>;<volume>18</volume>(<issue>6</issue>):<fpage>598</fpage>&#x02013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">18942660</pub-id></mixed-citation></ref><ref id="pon3794-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="pon3794-cit-0010">
<string-name>
<surname>Baum</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Torti</surname>
<given-names>D</given-names>
</string-name>. <article-title>Management of hot flashes in men with prostate cancer</article-title>. <source>Geriat Aging</source>
<year>2003</year>;<volume>6</volume>(<issue>2</issue>):<fpage>43</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="pon3794-cit-0011">
<string-name>
<surname>Siegel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Naishadham</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jemal</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cancer statistics</article-title>. <source>CA: A Cancer J Clin</source>
<year>2013</year>;<volume>63</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="pon3794-cit-0012">
<string-name>
<surname>Ayers</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hellier</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Effectiveness of group and self&#x02010;help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial</article-title>. <source>Menopause</source>
<year>2012</year>;<volume>19</volume>(<issue>7</issue>):<fpage>749</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">22336748</pub-id></mixed-citation></ref><ref id="pon3794-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="pon3794-cit-0013">
<string-name>
<surname>Mann</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hellier</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial</article-title>. <source>Lancet Oncol.</source>
<year>2012</year>; <volume>13</volume>(<issue>3</issue>):<fpage>309</fpage>&#x02013;<lpage>318</lpage>.<pub-id pub-id-type="pmid">22340966</pub-id></mixed-citation></ref><ref id="pon3794-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="pon3794-cit-0014">
<string-name>
<surname>Duijts</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>van Beurden</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Oldenburg</surname>
<given-names>HS</given-names>
</string-name>, et al. <article-title>Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment&#x02010;induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial</article-title>. <source>J. Clin. Oncol.</source>
<year>2012</year>;<volume>30</volume>(<issue>33</issue>):<fpage>4124</fpage>&#x02013;<lpage>4133</lpage>.<pub-id pub-id-type="pmid">23045575</pub-id></mixed-citation></ref><ref id="pon3794-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="pon3794-cit-0015">
<string-name>
<surname>Stefanopoulou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Telephone&#x02010;guided self&#x02010;help cognitive behavioural therapy for menopausal symptoms</article-title>. <source>Maturitas</source>
<year>2014</year>;<volume>77</volume>(<issue>1</issue>):<fpage>73</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">24144959</pub-id></mixed-citation></ref><ref id="pon3794-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="pon3794-cit-0016">
<string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>E</given-names>
</string-name>. <article-title>A cognitive model of menopausal hot flushes and night sweats</article-title>. <source>J. Psychosom. Res.</source>
<year>2010</year>;<volume>69</volume>(<issue>5</issue>):<fpage>491</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">20955869</pub-id></mixed-citation></ref><ref id="pon3794-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="pon3794-cit-0017">
<string-name>
<surname>Ayers</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Health&#x02010;related quality of life of women with menopausal hot flushes and night sweats</article-title>. <source>Climacteric</source>
<year>2013</year>;<volume>16</volume>:<fpage>235</fpage>&#x02013;<lpage>239</lpage>.<pub-id pub-id-type="pmid">22809134</pub-id></mixed-citation></ref><ref id="pon3794-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="pon3794-cit-0018">
<string-name>
<surname>Rand</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Otte</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Flockhart</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Modeling hot flushes and quality of life in breast cancer survivors</article-title>. <source>Climacteric</source>
<year>2011</year>;<volume>14</volume>:<fpage>171</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">20450413</pub-id></mixed-citation></ref><ref id="pon3794-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="pon3794-cit-0019">
<string-name>
<surname>Hanisch</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Donahue</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Validation of sternal skin conductance for detection of hot flashes in prostate cancer survivors</article-title>. <source>Psychophysiol</source>
<year>2007</year>;<volume>44</volume>(<issue>2</issue>):<fpage>189</fpage>&#x02013;<lpage>193</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="pon3794-cit-0020">
<string-name>
<surname>Yousaf</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Stefanopoulou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Grunfeld</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>A randomised controlled trial of a cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN): trial protocol</article-title>. <source>BMC Cancer</source>
<year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22212211</pub-id></mixed-citation></ref><ref id="pon3794-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="pon3794-cit-0021">
<string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>KL&#x02010;M</given-names>
</string-name>. <article-title>A psychological analysis of menopausal hot flushes</article-title>. <source>Brit J Clin Psychol</source>
<year>1995</year>;<volume>34</volume>(<issue>4</issue>):<fpage>589</fpage>&#x02013;<lpage>599</lpage>.<pub-id pub-id-type="pmid">8563666</pub-id></mixed-citation></ref><ref id="pon3794-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="pon3794-cit-0022">
<string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Cognitive behavioural interventions for the treatment of menopausal symptoms</article-title>. <source>Expert Rev Obstet Gynaecol</source>
<year>2012</year>;<volume>7</volume>(<issue>4</issue>):<fpage>321</fpage>&#x02013;<lpage>326</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="pon3794-cit-0023">
<string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Chilcot</surname>
<given-names>J</given-names>
</string-name>. <article-title>Testing a cognitive model of menopausal hot flushes and night sweats</article-title>. <source>J. Psychosom. Res.</source>
<year>2013</year>
<volume>74</volume>(<issue>4</issue>):<fpage>307</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">23497832</pub-id></mixed-citation></ref><ref id="pon3794-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="pon3794-cit-0024">
<string-name>
<surname>Eziefula</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Grunfeld</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>. <article-title>You know I've joined your club I'm the hot flush boy: a qualitative exploration of hot flushes and night sweats in men undergoing androgen deprivation therapy for prostate cancer</article-title>. <source>Psycho&#x02010;Oncology</source>
<year>2013</year>;<volume>22</volume>(<issue>12</issue>):<fpage>2823</fpage>&#x02013;<lpage>2830</lpage>.<pub-id pub-id-type="pmid">23893467</pub-id></mixed-citation></ref><ref id="pon3794-bib-0025"><label>25</label><mixed-citation publication-type="book" id="pon3794-cit-0025">
<string-name>
<surname>Beecham</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Knapp</surname>
<given-names>M</given-names>
</string-name>. In <source>Measuring Mental Health Needs</source>, <person-group person-group-type="editor"><name><surname>Thornicroft</surname><given-names>G</given-names></name></person-group> (ed.), <chapter-title>Costing psychiatric interventions</chapter-title>
<publisher-name>Gaskell</publisher-name>: <publisher-loc>London, UK</publisher-loc>, <year>2001</year>; <fpage>200</fpage>&#x02013;<lpage>224</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="pon3794-cit-0026">
<string-name>
<surname>Zigmond</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Snaith</surname>
<given-names>RP</given-names>
</string-name>. <article-title>The Hospital Anxiety and Depression Scale</article-title>. <source>Acta Psychiat Scand</source>
<year>1983</year>;<volume>67</volume>(<issue>6</issue>):<fpage>361</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">6880820</pub-id></mixed-citation></ref><ref id="pon3794-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="pon3794-cit-0027">
<string-name>
<surname>Fayers</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bottomley</surname>
<given-names>A</given-names>
</string-name>. <article-title>Quality of life research within the EORTC&#x02010;the EORTC QLQ&#x02010;C30</article-title>. <source>Europ J Cancer</source>
<year>2002</year>;<volume>38</volume>:<fpage>125</fpage>&#x02013;<lpage>133</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="pon3794-cit-0028">
<string-name>
<surname>van Andel</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bottomley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Foss&#x000e5;</surname>
<given-names>SD</given-names>
</string-name>, et al. <article-title>An international field study of the EORTC QLQ&#x02010;PR25: a questionnaire for assessing the health&#x02010;related quality of life of patients with prostate cancer</article-title>. <source>Europ J Cancer</source>
<year>2008</year>;<volume>44</volume>(<issue>16</issue>):<fpage>2418</fpage>&#x02013;<lpage>2424</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="pon3794-cit-0029">
<string-name>
<surname>Fife</surname>
<given-names>BL</given-names>
</string-name>. <article-title>The role of constructed meaning in adaptation to the onset of life&#x02010;threatening illness</article-title>. <source>Soc. Sci. Med.</source>
<year>2005</year>;<volume>61</volume>(<issue>10</issue>):<fpage>2132</fpage>&#x02013;<lpage>2143</lpage>.<pub-id pub-id-type="pmid">16026913</pub-id></mixed-citation></ref><ref id="pon3794-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="pon3794-cit-0030">
<string-name>
<surname>Mansfield</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Addis</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Courtenay</surname>
<given-names>W</given-names>
</string-name>. <article-title>Measurement of men's help seeking: development and evaluation of the barriers to help seeking scale</article-title>. <source>Psychol Men &#x00026; Masculinity</source>
<year>2005</year>;<volume>6</volume>(<issue>2</issue>):<fpage>95</fpage>&#x02013;<lpage>108</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="pon3794-cit-0031">
<string-name>
<surname>Barsky</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Wyshak</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Klerman</surname>
<given-names>GL</given-names>
</string-name>. <article-title>The Somatosensory Amplification Scale and its relationship to hypochondriasis</article-title>. <source>J. Psychiatr. Res.</source>
<year>1990</year>;<volume>24</volume>(<issue>4</issue>):<fpage>323</fpage>&#x02013;<lpage>334</lpage>.<pub-id pub-id-type="pmid">2090830</pub-id></mixed-citation></ref><ref id="pon3794-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="pon3794-cit-0032">
<string-name>
<surname>Herzberg</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Glaesmer</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hoyer</surname>
<given-names>J</given-names>
</string-name>. <article-title>Separating optimism and pessimism: a robust psychometric analysis of the Revised Life Orientation Test (LOT&#x02010;R)</article-title>. <source>Psychol. Assess.</source>
<year>2006</year>;<volume>18</volume>(<issue>4</issue>):<fpage>433</fpage>&#x02013;<lpage>438</lpage>.<pub-id pub-id-type="pmid">17154764</pub-id></mixed-citation></ref><ref id="pon3794-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="pon3794-cit-0033">
<string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Sharpley</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Stefanopoulou</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>The hot flush beliefs and behaviour scale for men (HFBBS&#x02010;Men) undergoing treatment for prostate cancer</article-title>. <source>Maturitas</source>
<year>2014</year>;<volume>79</volume>:<fpage>464</fpage>&#x02013;<lpage>470</lpage>.<pub-id pub-id-type="pmid">25449665</pub-id></mixed-citation></ref><ref id="pon3794-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="pon3794-cit-0034">
<string-name>
<surname>Bahr</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Webster</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Grady</surname>
<given-names>D</given-names>
</string-name>, D <article-title>Miniature ambulatory skin conductance monitor and algorithm for investigating hot flash events</article-title>. <source>Physiol Measurement</source>
<year>2014</year>;<volume>35</volume>(<issue>2</issue>):95.</mixed-citation></ref><ref id="pon3794-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="pon3794-cit-0035">
<string-name>
<surname>Stefanopoulou</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Does pattern recognition software using the Bahr monitor improve the sensitivity, specificity, and concordance of ambulatory skin conductance monitoring of hot flushes?</article-title>
<source>Menopause</source>
<year>2013</year>;<volume>20</volume>(<issue>11</issue>):<fpage>1</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">23266836</pub-id></mixed-citation></ref><ref id="pon3794-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="pon3794-cit-0036">
<string-name>
<surname>Irani</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Salomon</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Oba</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin&#x02010;releasing hormone analogues for prostate cancer: a double&#x02010;blind, randomised trial</article-title>. <source>Lancet Oncol.</source>
<year>2010</year>;<volume>11</volume>(<issue>2</issue>):<fpage>147</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">19963436</pub-id></mixed-citation></ref><ref id="pon3794-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="pon3794-cit-0037">
<string-name>
<surname>Hanisch</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Marcus</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Comparison of objective and patient&#x02010;reported hot flash measures in men with prostate cancer</article-title>. <source>J. Support. Oncol.</source>
<year>2009</year>;<volume>7</volume>(<issue>4</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pon3794-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="pon3794-cit-0038">
<string-name>
<surname>Watts</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leydon</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Birch</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Depression and anxiety in prostate cancer: a systematic review and meta&#x02010;analysis of prevalence rates</article-title>. <source>BMJ Open</source>
<year>2014</year>;<volume>4</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. DOI: <ext-link ext-link-type="doi" xlink:href="10.1136/bmjopen&#x02010;2013&#x02010;003901">10.1136/bmjopen&#x02010;2013&#x02010;003901</ext-link>.</mixed-citation></ref><ref id="pon3794-bib-0039"><label>39</label><mixed-citation publication-type="miscellaneous" id="pon3794-cit-0039">
<string-name>
<surname>Fayers</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Weeden</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Curran</surname>
<given-names>D</given-names>
</string-name>, 
<collab collab-type="authors" id="pon3794-gp-0001">on behalf of the EORTC Quality of Life Study Group</collab>
. <article-title>EORTC QLQ&#x02010;C30 Reference Values</article-title>. Brussels, EORTC, <year>1998</year>.</mixed-citation></ref><ref id="pon3794-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="pon3794-cit-0040">
<string-name>
<surname>Chilcot</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Norton</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hunter</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: who benefits and how does it work?</article-title>
<source>Maturitas</source>
<year>2014</year>;<volume>78</volume>(<issue>1</issue>):<fpage>56</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">24656221</pub-id></mixed-citation></ref></ref-list></back></article>